Stellar Capital Management LLC decreased its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 15,594 shares of the medical research company’s stock after selling 25 shares during the period. Thermo Fisher Scientific accounts for approximately 2.0% of Stellar Capital Management LLC’s portfolio, making the stock its 22nd largest holding. Stellar Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $2,721,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Proficio Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 71.5% during the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Chicago Partners Investment Group LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at approximately $108,000. Cribstone Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 8.7% during the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares during the period. Sharkey Howes & Javer raised its stake in Thermo Fisher Scientific by 1.0% during the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after purchasing an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the second quarter worth approximately $113,000. 83.66% of the stock is currently owned by institutional investors and hedge funds.

Shares of Thermo Fisher Scientific Inc (TMO) opened at $193.21 on Wednesday. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $201.20. The stock has a market cap of $77,604.64, a price-to-earnings ratio of 21.27, a PEG ratio of 1.77 and a beta of 1.08. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the prior year, the business earned $2.03 earnings per share. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. research analysts forecast that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.

WARNING: “Thermo Fisher Scientific Inc (TMO) Position Lessened by Stellar Capital Management LLC” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/08/thermo-fisher-scientific-inc-tmo-position-lessened-by-stellar-capital-management-llc.html.

TMO has been the topic of a number of recent analyst reports. BidaskClub raised shares of Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research note on Tuesday, July 11th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $200.00 price target (up previously from $195.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 13th. Barclays PLC reaffirmed an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 17th. Finally, Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Thermo Fisher Scientific has an average rating of “Buy” and an average price target of $205.71.

In related news, Director C Martin Harris sold 360 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the completion of the sale, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction on Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the sale, the director now directly owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Insiders sold 22,738 shares of company stock valued at $4,021,512 in the last three months. Company insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.